187 related articles for article (PubMed ID: 21057458)
21. New developments in breast cancer prognosis: molecular predictors of treatment response and survival.
Foo EM; Boost MV; Wong AS; Loo WT; Chow LW; Chow CY
Int J Biol Markers; 2013 Jun; 28(2):131-40. PubMed ID: 23709349
[TBL] [Abstract][Full Text] [Related]
22. Hormone receptors and HER-2 status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative Asian patients treated with breast conservation therapy.
Wong FY; Chin FK; Lee KA; Soong YL; Chua ET
Ann Acad Med Singap; 2011 Feb; 40(2):90-6. PubMed ID: 21468463
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
24. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
[No Abstract] [Full Text] [Related]
25. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
[TBL] [Abstract][Full Text] [Related]
27. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Lv M; Li B; Li Y; Mao X; Yao F; Jin F
Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
31. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
32. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
33. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
[TBL] [Abstract][Full Text] [Related]
34. Correlation of B-cell lymphoma 2 immunoexpression in invasive carcinoma of breast, no special type with hormone receptor status, proliferation index, and molecular subtypes.
Azmat H; Faridi J; Habib HM; Bugti UJ; Sheikh AK; Riaz SK
J Cancer Res Ther; 2022 Dec; 18(Supplement):S313-S319. PubMed ID: 36510982
[TBL] [Abstract][Full Text] [Related]
35. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
[TBL] [Abstract][Full Text] [Related]
36. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.
Carvalho FM; Bacchi LM; Pincerato KM; Van de Rijn M; Bacchi CE
BMC Womens Health; 2014 Aug; 14():102. PubMed ID: 25174527
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
38. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes.
Smid M; Hoes M; Sieuwerts AM; Sleijfer S; Zhang Y; Wang Y; Foekens JA; Martens JW
Breast Cancer Res Treat; 2011 Jul; 128(1):23-30. PubMed ID: 20632083
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
40. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer.
Kim SK; Jung WH; Koo JS
Int J Clin Exp Pathol; 2014; 7(6):3224-34. PubMed ID: 25031743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
